Implied DSI Analyst Target Price: $130
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2025
0mins
Should l Buy MD?
Source: NASDAQ.COM
ETF Analyst Target Prices: The iShares ESG MSCI KLD 400 ETF (DSI) has an implied analyst target price of $129.70, indicating a potential upside of 20.83% from its current trading price of $107.34.
Notable Holdings with Upside Potential: Key underlying holdings such as Teradata Corp, Pediatrix Medical Group Inc, and Teladoc Health Inc show significant upside potential based on analysts' target prices, raising questions about the validity of these targets amidst market developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MD
Wall Street analysts forecast MD stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 21.970
Low
23.00
Averages
23.50
High
24.00
Current: 21.970
Low
23.00
Averages
23.50
High
24.00
About MD
Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Pediatrix Medical Group Set to Announce Q4 Earnings
- Earnings Announcement Date: Pediatrix Medical Group is set to release its Q4 earnings report on February 19 before the market opens, drawing significant attention that could impact the company's stock performance.
- Earnings Expectations: The consensus EPS estimate stands at $0.54, reflecting a year-over-year increase of 5.9%, indicating a slight improvement in profitability that may bolster investor confidence.
- Revenue Expectations: The revenue estimate is projected at $486.23 million, representing a year-over-year decline of 3.1%, highlighting challenges in revenue growth that could influence future investment decisions.
- Historical Performance: Over the past two years, Pediatrix Medical Group has beaten EPS estimates 88% of the time and revenue estimates 63% of the time, demonstrating the company's stability and adaptability in earnings announcements.
See More
Pediatrix Medical Group Reports Q4 2025 Earnings Results
- Financial Performance Overview: Pediatrix Medical Group reported net revenue of $494 million and net income of $34 million for Q4 2025, with an adjusted EPS of $0.50, indicating stable operational capacity despite a slight decline in revenue compared to the previous year, aligning with the company's upwardly revised expectations.
- Same-Unit Revenue Growth: The same-unit revenue increased by 4.0% in Q4 2025, primarily driven by improved collection activities and higher patient acuity, although patient service volumes decreased by 2.7%, demonstrating resilience in market demand, particularly in hospital-based services.
- Cost Control and Adjustments: Operating expenses for Q4 were $444 million, down from $463 million in the prior year, mainly due to the impact of practice dispositions, despite rising clinical compensation costs, reflecting the company's efforts in cost management.
- Future Outlook: Pediatrix anticipates its 2026 adjusted EBITDA to range between $280 million and $300 million, showcasing confidence in future growth, particularly as the company continues to invest in innovation and service quality amid challenges in the healthcare industry.
See More
Pediatrix Medical Group Q4 Earnings Analysis
- Earnings Performance: Pediatrix Medical Group reported a Q4 non-GAAP EPS of $0.50, missing estimates by $0.04, indicating pressure on profitability that may affect investor confidence.
- Revenue Trends: The company's Q4 revenue was $494 million, a 1.6% year-over-year decline, although it beat market expectations by $7.77 million, reflecting challenges faced by the business, particularly from practice dispositions.
- Net Revenue Analysis: For the three months ending December 31, 2025, net revenue was $493.8 million, down from $502.4 million in the prior year, primarily due to the impact of non-same unit activity, indicating insufficient adaptability in the market.
- Future Outlook: Pediatrix anticipates its 2026 Adjusted EBITDA to range between $280 million and $300 million, showing potential for growth despite challenges, which may provide a basis for future strategic adjustments.
See More
Pediatrix Medical Group to Host Investor Conference Call
- Investor Conference Call: Pediatrix Medical Group will host an investor conference call on February 19, 2026, at 9:00 a.m. ET to discuss operational results for the quarter ended December 31, 2025, which is expected to provide crucial financial and operational insights to investors.
- Webcast Access: The conference call will be webcasted via Pediatrix's website, allowing investors to access the call at www.pediatrix.com/investors, ensuring broad participation and transparent information dissemination.
- Company Background: Founded in 1979, Pediatrix now boasts approximately 4,400 affiliated physicians, focusing on medical services for women, babies, and children across specialties such as obstetrics, maternal-fetal medicine, and neonatology, highlighting its leadership in the healthcare sector.
- Forward-Looking Statements: The press release includes forward-looking statements that outline the company's future objectives and plans, although these statements do not guarantee future performance, they provide investors with insights into the company's strategic direction.
See More
Midland Exploration Inc. Initiates 1,600-Metre Drilling Program on Jouvex Gold Property
- Drilling Program Launch: Midland Exploration has initiated a 1,600-metre drilling program on its Jouvex gold property, aimed at testing magnetic anomalies associated with IP anomalies, which is expected to provide crucial data on the area's gold potential.
- Historical Data Reevaluation: By reassessing historical drilling data, Midland has identified the southern part of the Jouvex project as the main area for current exploration efforts, indicating potential for VMS mineralization that may attract further investment.
- New Target Identification: In the southern project area, Midland has identified potential syenitic intrusions similar to the Douay gold deposit, which could become a key area for future gold development, further enhancing the company's strategic positioning.
- Partnerships: Midland has established partnerships with several reputable mining companies, demonstrating its strong intent to discover world-class gold and critical metal deposits in Quebec, which is expected to drive future growth for the company.
See More
Mid-Cap ETFs Experience Strong Momentum: Is Further Growth on the Horizon?
Mid-Cap Investing Appeal: Mid-cap stocks offer a balance of resilience and growth potential, currently showing strong performance with many ETFs reaching 52-week highs, despite the risks compared to large and small caps.
Global Economic Outlook: The IMF projects a decline in global growth rates, with developed economies growing slowly, which may lead investors to be cautious about large-cap stocks due to their foreign exposure.
Federal Reserve Actions: The Fed has implemented three rate cuts this year, with projections indicating a controlled outlook for GDP growth and unemployment rates, favoring domestically-focused stocks like small and mid-caps.
Mid-Cap ETFs Performance: Several mid-cap ETFs have outperformed the SPDR S&P 500 ETF Trust recently, with notable gains over the past month, suggesting a favorable investment opportunity in this segment.
See More
Pediatrix Medical Group Set to Announce Q4 Earnings
- Earnings Announcement Date: Pediatrix Medical Group is set to release its Q4 earnings report on February 19 before the market opens, drawing significant attention that could impact the company's stock performance.
- Earnings Expectations: The consensus EPS estimate stands at $0.54, reflecting a year-over-year increase of 5.9%, indicating a slight improvement in profitability that may bolster investor confidence.
- Revenue Expectations: The revenue estimate is projected at $486.23 million, representing a year-over-year decline of 3.1%, highlighting challenges in revenue growth that could influence future investment decisions.
- Historical Performance: Over the past two years, Pediatrix Medical Group has beaten EPS estimates 88% of the time and revenue estimates 63% of the time, demonstrating the company's stability and adaptability in earnings announcements.
See More
Pediatrix Medical Group Reports Q4 2025 Earnings Results
- Financial Performance Overview: Pediatrix Medical Group reported net revenue of $494 million and net income of $34 million for Q4 2025, with an adjusted EPS of $0.50, indicating stable operational capacity despite a slight decline in revenue compared to the previous year, aligning with the company's upwardly revised expectations.
- Same-Unit Revenue Growth: The same-unit revenue increased by 4.0% in Q4 2025, primarily driven by improved collection activities and higher patient acuity, although patient service volumes decreased by 2.7%, demonstrating resilience in market demand, particularly in hospital-based services.
- Cost Control and Adjustments: Operating expenses for Q4 were $444 million, down from $463 million in the prior year, mainly due to the impact of practice dispositions, despite rising clinical compensation costs, reflecting the company's efforts in cost management.
- Future Outlook: Pediatrix anticipates its 2026 adjusted EBITDA to range between $280 million and $300 million, showcasing confidence in future growth, particularly as the company continues to invest in innovation and service quality amid challenges in the healthcare industry.
See More
Pediatrix Medical Group Q4 Earnings Analysis
- Earnings Performance: Pediatrix Medical Group reported a Q4 non-GAAP EPS of $0.50, missing estimates by $0.04, indicating pressure on profitability that may affect investor confidence.
- Revenue Trends: The company's Q4 revenue was $494 million, a 1.6% year-over-year decline, although it beat market expectations by $7.77 million, reflecting challenges faced by the business, particularly from practice dispositions.
- Net Revenue Analysis: For the three months ending December 31, 2025, net revenue was $493.8 million, down from $502.4 million in the prior year, primarily due to the impact of non-same unit activity, indicating insufficient adaptability in the market.
- Future Outlook: Pediatrix anticipates its 2026 Adjusted EBITDA to range between $280 million and $300 million, showing potential for growth despite challenges, which may provide a basis for future strategic adjustments.
See More
Pediatrix Medical Group to Host Investor Conference Call
- Investor Conference Call: Pediatrix Medical Group will host an investor conference call on February 19, 2026, at 9:00 a.m. ET to discuss operational results for the quarter ended December 31, 2025, which is expected to provide crucial financial and operational insights to investors.
- Webcast Access: The conference call will be webcasted via Pediatrix's website, allowing investors to access the call at www.pediatrix.com/investors, ensuring broad participation and transparent information dissemination.
- Company Background: Founded in 1979, Pediatrix now boasts approximately 4,400 affiliated physicians, focusing on medical services for women, babies, and children across specialties such as obstetrics, maternal-fetal medicine, and neonatology, highlighting its leadership in the healthcare sector.
- Forward-Looking Statements: The press release includes forward-looking statements that outline the company's future objectives and plans, although these statements do not guarantee future performance, they provide investors with insights into the company's strategic direction.
See More
Midland Exploration Inc. Initiates 1,600-Metre Drilling Program on Jouvex Gold Property
- Drilling Program Launch: Midland Exploration has initiated a 1,600-metre drilling program on its Jouvex gold property, aimed at testing magnetic anomalies associated with IP anomalies, which is expected to provide crucial data on the area's gold potential.
- Historical Data Reevaluation: By reassessing historical drilling data, Midland has identified the southern part of the Jouvex project as the main area for current exploration efforts, indicating potential for VMS mineralization that may attract further investment.
- New Target Identification: In the southern project area, Midland has identified potential syenitic intrusions similar to the Douay gold deposit, which could become a key area for future gold development, further enhancing the company's strategic positioning.
- Partnerships: Midland has established partnerships with several reputable mining companies, demonstrating its strong intent to discover world-class gold and critical metal deposits in Quebec, which is expected to drive future growth for the company.
See More
Mid-Cap ETFs Experience Strong Momentum: Is Further Growth on the Horizon?
Mid-Cap Investing Appeal: Mid-cap stocks offer a balance of resilience and growth potential, currently showing strong performance with many ETFs reaching 52-week highs, despite the risks compared to large and small caps.
Global Economic Outlook: The IMF projects a decline in global growth rates, with developed economies growing slowly, which may lead investors to be cautious about large-cap stocks due to their foreign exposure.
Federal Reserve Actions: The Fed has implemented three rate cuts this year, with projections indicating a controlled outlook for GDP growth and unemployment rates, favoring domestically-focused stocks like small and mid-caps.
Mid-Cap ETFs Performance: Several mid-cap ETFs have outperformed the SPDR S&P 500 ETF Trust recently, with notable gains over the past month, suggesting a favorable investment opportunity in this segment.
See More
